ECSP109918A - Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígeno - Google Patents
Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígenoInfo
- Publication number
- ECSP109918A ECSP109918A EC2010009918A ECSP109918A ECSP109918A EC SP109918 A ECSP109918 A EC SP109918A EC 2010009918 A EC2010009918 A EC 2010009918A EC SP109918 A ECSP109918 A EC SP109918A EC SP109918 A ECSP109918 A EC SP109918A
- Authority
- EC
- Ecuador
- Prior art keywords
- aurora
- inhibitor
- quinasa
- combination
- target treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epoxy Compounds (AREA)
Abstract
La presente invención se refiere a un método de tratamiento de cáncer por pretratamiento con agentes antimitóticos seguido de al menos un inhibidor de aurora quinasa. Se proveen extensas ilustraciones para los agentes antimitóticos e inhibidores de aurora quinasa que son de utilidad en el tratamiento de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95308707P | 2007-07-31 | 2007-07-31 | |
US2398508P | 2008-01-28 | 2008-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP109918A true ECSP109918A (es) | 2010-02-26 |
Family
ID=40305124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010009918A ECSP109918A (es) | 2007-07-31 | 2010-01-29 | Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígeno |
Country Status (17)
Country | Link |
---|---|
US (1) | US20100249030A1 (es) |
EP (1) | EP2182986A2 (es) |
JP (1) | JP2010535201A (es) |
KR (1) | KR20100042287A (es) |
CN (1) | CN101808666A (es) |
AR (1) | AR068048A1 (es) |
AU (1) | AU2008282885A1 (es) |
BR (1) | BRPI0814874A2 (es) |
CA (1) | CA2694218A1 (es) |
CL (1) | CL2008002224A1 (es) |
CO (1) | CO6331446A2 (es) |
EC (1) | ECSP109918A (es) |
MX (1) | MX2010001340A (es) |
PE (1) | PE20090902A1 (es) |
RU (1) | RU2010106878A (es) |
TW (1) | TW200911241A (es) |
WO (1) | WO2009017701A2 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054701A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
US8318735B2 (en) * | 2006-10-31 | 2012-11-27 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
WO2009097233A1 (en) * | 2008-01-28 | 2009-08-06 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
EP2470183B1 (en) * | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
US8435976B2 (en) * | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
MX2012004990A (es) | 2009-10-30 | 2012-06-12 | Janssen Pharmaceutica Nv | Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10. |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
CN103038235B (zh) | 2010-06-01 | 2015-07-29 | 拜耳知识产权有限责任公司 | 取代的咪唑并吡嗪 |
EP2651950A1 (en) * | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
CN103204824B (zh) * | 2012-01-12 | 2015-04-08 | 清华大学深圳研究生院 | 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9669035B2 (en) | 2012-06-26 | 2017-06-06 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders |
RU2667058C2 (ru) | 2012-07-09 | 2018-09-14 | Янссен Фармацевтика Нв | Ингибиторы фермента фосфодиэстеразы 10 |
WO2014066304A1 (en) * | 2012-10-22 | 2014-05-01 | Egenix, Inc. | Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
MX2015009057A (es) * | 2013-01-15 | 2015-10-05 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. |
TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 |
JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
BR112016018555B1 (pt) | 2014-02-13 | 2024-01-23 | Incyte Holdings Corporation | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
SG11201606689VA (en) | 2014-02-13 | 2016-09-29 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9321766B1 (en) | 2014-10-06 | 2016-04-26 | Allergan, Inc. | Kinase inhibitors |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
AU2017252328B2 (en) | 2016-04-22 | 2023-02-23 | Incyte Corporation | Formulations of an LSD1 inhibitor |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
CN112533903B (zh) * | 2018-06-26 | 2022-08-16 | 昆药集团股份有限公司 | 苯并咪唑衍生物及其作为idh1抑制剂的应用 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
AR117472A1 (es) | 2018-12-21 | 2021-08-11 | Celgene Corp | Inhibidores de tienopiridina de ripk2 |
US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
WO2024088192A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | An aurora a inhibitor for use in treatments of cancers |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576085B2 (en) * | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
DE60317353T2 (de) * | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
WO2005002571A1 (en) * | 2003-07-03 | 2005-01-13 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
US7608643B2 (en) * | 2005-03-09 | 2009-10-27 | Schering Corporation | Compounds for inhibiting KSP kinesin activity |
JP2008533019A (ja) * | 2005-03-09 | 2008-08-21 | シェーリング コーポレイション | Kspキネシン活性を阻害するための化合物 |
AR056785A1 (es) * | 2005-11-10 | 2007-10-24 | Schering Corp | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS |
-
2008
- 2008-07-28 CN CN200880109598A patent/CN101808666A/zh active Pending
- 2008-07-28 RU RU2010106878/15A patent/RU2010106878A/ru unknown
- 2008-07-28 BR BRPI0814874A patent/BRPI0814874A2/pt not_active IP Right Cessation
- 2008-07-28 US US12/670,762 patent/US20100249030A1/en not_active Abandoned
- 2008-07-28 WO PCT/US2008/009108 patent/WO2009017701A2/en active Application Filing
- 2008-07-28 CA CA2694218A patent/CA2694218A1/en not_active Abandoned
- 2008-07-28 JP JP2010519219A patent/JP2010535201A/ja not_active Withdrawn
- 2008-07-28 MX MX2010001340A patent/MX2010001340A/es not_active Application Discontinuation
- 2008-07-28 KR KR1020107004497A patent/KR20100042287A/ko not_active Application Discontinuation
- 2008-07-28 EP EP08794799A patent/EP2182986A2/en not_active Withdrawn
- 2008-07-28 AU AU2008282885A patent/AU2008282885A1/en not_active Abandoned
- 2008-07-29 CL CL2008002224A patent/CL2008002224A1/es unknown
- 2008-07-29 AR ARP080103276A patent/AR068048A1/es not_active Application Discontinuation
- 2008-07-29 TW TW097128711A patent/TW200911241A/zh unknown
- 2008-07-30 PE PE2008001275A patent/PE20090902A1/es not_active Application Discontinuation
-
2010
- 2010-01-29 EC EC2010009918A patent/ECSP109918A/es unknown
- 2010-01-29 CO CO10009533A patent/CO6331446A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2010535201A (ja) | 2010-11-18 |
EP2182986A2 (en) | 2010-05-12 |
CO6331446A2 (es) | 2011-10-20 |
TW200911241A (en) | 2009-03-16 |
CL2008002224A1 (es) | 2009-07-17 |
US20100249030A1 (en) | 2010-09-30 |
KR20100042287A (ko) | 2010-04-23 |
AU2008282885A1 (en) | 2009-02-05 |
RU2010106878A (ru) | 2011-09-10 |
WO2009017701A2 (en) | 2009-02-05 |
PE20090902A1 (es) | 2009-07-25 |
CA2694218A1 (en) | 2009-02-05 |
CN101808666A (zh) | 2010-08-18 |
MX2010001340A (es) | 2010-06-02 |
BRPI0814874A2 (pt) | 2019-09-24 |
AR068048A1 (es) | 2009-11-04 |
WO2009017701A3 (en) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP109918A (es) | Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígeno | |
NI201000084A (es) | Tratamiento de cáncer de ovarios con un compuesto yodonitrobenzamida en combinación con agentes anti-tumorales | |
CR11485A (es) | Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
DOP2010000280A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
CR20120115A (es) | Terapia de combinacion con composiciones de nanoparticulas de taxano e inhibidores de hedgehog | |
ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
SV2009003227A (es) | Composiciones de inhibidores de chk 1 ref. x-17672 | |
ECSP11010798A (es) | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa | |
AR080872A1 (es) | Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad | |
MX2010009765A (es) | Moleculas pequeñas que contienen boro como agentes anti-inflamatorios. | |
AR053865A1 (es) | Composiciones y metodos para el tratamiento de neoplasmas | |
CL2008003653A1 (es) | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. | |
CR20110103A (es) | Heteroarilos sustituidos | |
BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
CL2008001057A1 (es) | Agente para el tratamiento de micosis producida por saprolegnia, achlya y/o aphanomyces en peces, el cual comprende al menos un fungicida seleccionado entre a) inhibidores de l a mitosis y division celular, b) inhiidores de la sintesis de ergosterol o, c) derivados de piridina, benzopiranona, carbonitrilo,quinolinas, entre otras. | |
NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
ECSP11011405A (es) | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r | |
PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
NI201100035A (es) | Agentes antifúngicos. | |
BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
ECSP099836A (es) | Macrociclos y sus usos | |
CR20110239A (es) | Composiciones y métodos de uso para variantes de trombomodulina | |
UY32215A (es) | Inhibidores de la s1p liasa para el tratamiento de malaria cerebral |